Cellular origin of glioblastoma and its implication in precision therapy

摘要

Glioblastoma(GBM)is the most common malignant primary tumor in the central nervous system.Despite advances in neurosurgery,radiation therapy and chemotherapy,the median survival time of GBM patients is only 9 to 16 months.1 Therefore,GBM is considered one of the deadliest human cancers.In the past two decades,many efforts have been made by scientists and clinicians to develop new drugs to improve current therapies.Unfortunately,most efforts have not achieved long-term remissions in clinical trials,even though some of them are promising in animal models,making treatment options still limited.